RXRX Extends Tempus Deal As Stock Climbs On Predictable Cash

Recursion Pharmaceuticals Inc. stocks have been trading up by 4.16 percent following upbeat AI-driven drug discovery partnership news.

Live Update At 15:02:20 EDT: On Tuesday, September 22, 2026 Recursion Pharmaceuticals Inc. stock [NASDAQ: RXRX] is trending up by 4.16%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

RXRX has been grinding higher on the chart. Over the last few weeks, Recursion Pharmaceuticals stock climbed from the mid‑$3s to close near $4.13, showing a steady uptrend rather than a wild spike. For active traders, that controlled push matters. It signals accumulation, not just a one-day headline pump.

Intraday, RXRX traded in a tight $3.90–$4.16 range with lots of liquidity around $4. That clean range gives short-term traders clear risk levels. A break above the recent $4.16 high can attract momentum players, while a crack back under $3.90 would warn that the current move is fading.

Fundamentally, RXRX is still a classic high-burn biotech platform story. Revenue sits around $74.3M, but margins are brutal, with EBITDA deeply negative and free cash flow at about -$108M last quarter. The company does, however, hold roughly $545.7M in cash and short-term investments and carries very little debt, which buys time.

Valuation is rich, with a price-to-sales ratio over 38 and negative earnings, so RXRX trades on pipeline and platform potential, not current profits. That backdrop makes news like the Tempus deal vital for sentiment and for how traders frame the risk/reward.

Why Traders Are Watching RXRX After The Tempus Deal

Traders are locked in on RXRX this week because the Tempus AI news hits all the right themes: AI, data, and predictable cash. Recursion Pharmaceuticals extended its data license agreement with Tempus to 2029, turning a nearer-term, more discretionary setup into a longer, more stable one. Tempus will now pay $42M in committed license fees over three years instead of up to $84M in discretionary payments over two years.

On paper, RXRX gives up some headline upside. In practice, the market told you exactly what it thinks. RXRX jumped about 2.6% after the announcement. Traders clearly preferred guaranteed money to theoretical maximums that may never show up. In this kind of speculative biotech, certainty is a real asset.

The other key piece is tech validation. RXRX granted Tempus a new non‑exclusive, worldwide license to its proprietary RNA foundation model, TxFM. That phrase — “non‑exclusive worldwide license” — should catch every growth trader’s eye. It means Tempus can use the model, but Recursion Pharmaceuticals is still free to license TxFM to others. That keeps the door open for more AI‑data deals while locking in one anchor partner.

For RXRX, the story is now clearer: a heavy cash-burn platform with a large war chest, pricey valuation, and a flagship AI partnership that just got de‑risked and extended. For short-term trading, this kind of positive, fundamentals‑linked catalyst often sets the stage for continuation moves — especially if RXRX holds above $4 and grinds higher on volume.

The Form 4 insider filings in recent weeks add some noise but not much signal. With no public detail on whether those RXRX trades were buys, sells, or equity awards, serious traders will treat them as routine background rather than a strong directional tell.

Conclusion

RXRX is a classic example of how story and structure can shift a chart. Recursion Pharmaceuticals was already creeping up from the low $3s, but the Tempus AI news gave traders a clean narrative: more predictable cash, longer runway, and clear third‑party validation of its RNA model TxFM.

Nothing in the numbers changes the fact that RXRX is highly speculative. Losses are large, margins are ugly, and the stock trades at a steep price-to-sales multiple. But the balance sheet shows over half a billion dollars in cash and limited debt, which keeps the focus on execution and deal flow rather than survival. For active traders, that combo — strong cash, painful income statement, and big AI‑driven optionality — is exactly what creates volatility and opportunity.

The key levels are straightforward. On the upside, watch that recent $4.16 area from the intraday high; sustained trading above it can trigger more momentum into the mid‑$4s. On the downside, a break back under $3.80–$3.90 would warn that the Tempus enthusiasm is fading and RXRX may need another catalyst.

As Tim Sykes pounds into his students, “The market doesn’t care about your opinion, it cares about price action — react to what the chart is telling you, not what you wish would happen.” As millionaire penny stock trader and teacher Tim Sykes, says, “Small gains add up over time; focus on building wealth gradually, not chasing jackpots.”. With RXRX, that means respecting the uptrend, knowing the risks, and being ready to cut losses fast if the Tempus‑driven move runs out of gas. This is educational and research material only, but the setup around RXRX is one every active trader should study closely.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks